Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Q-linea AB ( (SE:QLINEA) ) has shared an update.
Q-linea AB has signed a contract for the adoption of its ASTar® rapid antibiotic susceptibility testing system by a large independent health system in the southeastern United States, specializing in cancer and pediatric care, following an evaluation begun in 2025. The deal marks further U.S. traction for Q-linea’s flagship technology, underscoring the company’s push to expand its presence in high-acuity hospital settings where faster, more precise infection diagnostics can improve outcomes for vulnerable patient groups and support efforts against antimicrobial resistance.
The most recent analyst rating on (SE:QLINEA) stock is a Hold with a SEK26.00 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
More about Q-linea AB
Q-linea AB is a Sweden-based infection diagnostics company focused on rapid Antibiotic Susceptibility Testing (rAST) to support the treatment of sepsis and other severe infections. Its flagship product, the fully automated ASTar® system, delivers rapid phenotypic AST results directly from positive blood cultures in about six hours, enabling faster, targeted antibiotic therapy and helping combat antimicrobial resistance. Founded in 2008 and headquartered in Uppsala, Q-linea is listed on Nasdaq Stockholm and targets hospitals and healthcare providers globally seeking to improve infectious disease management and reduce healthcare costs.
YTD Price Performance: 8.44%
Average Trading Volume: 13,145
Technical Sentiment Signal: Sell
Current Market Cap: SEK503.6M
For a thorough assessment of QLINEA stock, go to TipRanks’ Stock Analysis page.